Company: CSTL
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001447362-25-000069
Chunk: 101

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-05-05
Form: 10-Q
Item: Item 8
Chunk 101
---
4.Disaggregation of RevenuesThe table below provides the disaggregation of revenue by type (in thousands):Three Months EndedMarch 31,20252024Dermatologic(1)$62,962 $59,334 Non-Dermatologic(2)25,026 13,640 Total net revenues$87,988 $72,974 (1)Consists of DecisionDx-Melanoma, DecisionDx-SCC and our Diagnostic Gene Expression Profile offering.(2)Consists of TissueCypher, DecisionDx-UM and IDgenetix. 

11

Table of ContentsCASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(UNAUDITED)

We have presented disaggregated net revenues included in our single reportable segment in the table above. The characteristics for each test in our single segment are similar, with each test having a single performance obligation. Our CODM is the single individual responsible for managing our segment and reviews consolidated results and budgets in assessing performance and in allocating resources. See Note 14 for additional information about our reportable segment.Payor ConcentrationWe rely upon reimbursements from third-party government payors (primarily Medicare) and private-payor insurance companies to collect accounts receivable related to sales of our tests.Our significant third-party payors and their related revenues as a percentage of total revenues and accounts receivable balances were as follows: Percentage of Revenues Three Months EndedMarch 31,Percentage of Accounts Receivable (current) as ofPercentage of Accounts Receivable (noncurrent) as of 20252024March 31, 2025December 31, 2024March 31, 2025December 31, 2024Medicare47 %49 %21 %18 %**Payor A15 %14 %16 %19 %15 %15 %Payor B**22 %20 %11 %12 %*    Less than 10%There were no other third-party payors that individually accounted for more than 10% of our total revenue or accounts receivable for the periods shown in the table above.

4. Loss Per Share

Basic loss per share is computed by dividing net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the additional dilution from potential issuances of common stock